Final results of ANICCA-Class II, a single arm, open-label phase II trial assessing nivolumab in tissue-specific class II expressing metastatic microsatellite stable colorectal cancer, with a parallel assessment of the immunoscore-immune checkpoint a

In pMMR CRC, tsMHC-II positivity fails to identify a subset of patients with metastatic pMMR CRC obtaining potentially meaningful benefit from single-agent anti-PD-1. Although numbers are limited, there is no clear evidence that IS-IC is predictive of outcome with single-agent anti-PD-1. The poor outcome in those with LM underscores the need for therapies that overcome the systemic immunosuppression driven by LM.

Authors

Institutions

Publication Details

Journal
Journal for ImmunoTherapy of Cancer
Published
2025-12-01
DOI
https://doi.org/10.1136/jitc-2025-012749
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Final results of ANICCA-Class II, a single arm, open-label phase II trial assessing nivolumab in tissue-specific class II expressing metastatic microsatellite stable colorectal cancer, with a parallel assessment of the immunoscore-immune checkpoint a

Lucinda Jane Billingham, Joshua Savage, Charlotte Gaskell, Daniel H. Palmer et al.
Journal for ImmunoTherapy of Cancer
Cancer Immunotherapy and Biomarkers
article

Final results of ANICCA-Class II, a single arm, open-label phase II trial assessing nivolumab in tissue-specific class II expressing metastatic microsatellite stable colorectal cancer, with a parallel assessment of the immunoscore-immune checkpoint a

Lucinda Jane Billingham, Joshua Savage, Charlotte Gaskell, Daniel H. Palmer, Sally Clive, Gary Middleton, Mark Saunders, Ruth Plummer, David Cunningham, Anne Thomas, Vicky M. Coyle, John A. Bridgewater, Paul J. Ross, Phillipe Taniere
article en

Abstract

In pMMR CRC, tsMHC-II positivity fails to identify a subset of patients with metastatic pMMR CRC obtaining potentially meaningful benefit from single-agent anti-PD-1. Although numbers are limited, there is no clear evidence that IS-IC is predictive of outcome with single-agent anti-PD-1. The poor outcome in those with LM underscores the need for therapies that overcome the systemic immunosuppression driven by LM.

Journal for ImmunoTherapy of CancerVol. 13(12)
Guy's Hospital (GB), University Hospitals Birmingham NHS Foundation Trust (GB), University College London Hospitals NHS Foundation Trust (GB), University of Ulster (GB), Western General Hospital (GB), Leicester Royal Infirmary (GB), Belfast City Hospital (GB), Clatterbridge Cancer Centre NHS Foundation Trust (GB), Royal Marsden Hospital (GB), The Christie Hospital (GB), Cancer Research UK Clinical Trials Unit (GB), University College London (GB), University of Birmingham (GB), Newcastle University (GB)
Openalex Percentile: Top 44%
Cancer Immunotherapy and Biomarkers
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.